top of page

March 2020 through November 30, 2021

Oura Ring 06.jpg


What was the first TemPredict Study?

This was a research study to observe associations between dermal body temperature, heart rate and related metrics, and onset of symptoms such as fever, cough, and fatigue, which can characterize COVID-19.

The purpose of this study was to collect information from a wearable sensor that may allow researchers to develop an algorithm that can predict onset of symptoms such as fever, cough, and fatigue, which can characterize COVID-19.

The study used an Oura Ring which is a wearable device that measures heart rate, inter-beat interval and changes in dermal temperature and is associated with a smartphone app.

Who were qualified for the study?


Two groups of people were qualified to participate: 


1. Healthcare Employees at Recruitment Sites

  • Employee who works in a healthcare environment with potential contact with patients seeking treatment for symptoms such as fever, cough, and fatigue, which can characterize COVID-19

  • May or may not own an Oura Ring

2. Adult Volunteers

  • Must personally own an Oura Ring

List of Recruitment Sites (NOW CLOSED) where TemPredict provided study rings:

  • American Medical Response (AMR) 

  • Beth Israel Deaconess Medical Center

  • Boston Medical Center

  • Florida Atlantic University

  • Jamaica Hospital Medical Center

  • Norcal Ambulance

  • Northwestern University

  • New York Presbyterian - Lower Manhattan Hospital

  • New York Presbyterian - Methodist

  • New York Presbyterian - Queens

  • New York Presbyterian - Weill Cornell

  • Santa Clara Valley Medical Center (SCVMC)

  • SCVMC - O'Connor Hospital

  • SCVMC - Saint Louise Regional Hospital

  • Stanford University

  • Stony Brook University

  • Tufts Medical Center

  • University of California, Los Angeles (UCLA)

  • UCLA - Olive View

  • UCLA - Ronald Reagan

  • University of California, San Francisco (UCSF)

  • University of Miami

  • University of Miami - Bascom Palmar Eye Center

  • University of Miami - Health Tower

  • University of Miami - Jackson Memorial Hospital 

  • University of Miami - Lennar Medical Center

  • University of Miami - Ryder Trauma Center

  • UT Southwestern Medical Center

  • UT Southwestern - Parkland Hospital

  • UT Southwestern - William P. Clements Jr. University Hospital

  • Zuckerberg San Francisco General Hospital

What did participation involve?


Healthcare Employees at Recruitment Sites

  • Downloaded the Oura Ring App on your smartphone

  • Completed a Screening and Baseline Survey online

  • Received an Oura Ring shipped to you via FedEx 

  • Wore an Oura ring until November 30, 2020

  • Completed daily surveys indicating whether you were experiencing any symptoms that characterize COVID-19, such as fever, cough, fatigue, or other symptoms

  • Shared data collected by the Oura Ring App (including temperature, heart rate, respiratory rate, sleep, and activity) with Oura, Inc.

  • Returned the Oura Ring via FedEx in a pre-paid, study-supplied shipping package


Adult Volunteers who personally own an Oura Ring

  • Completed a Screening and Baseline Survey online

  • Completed daily surveys indicating whether you were experiencing any illness symptoms until November 30, 2020

  • Shared data collected by the Oura Ring App (including temperature, heart rate, respiratory rate, sleep, and activity) with Oura, Inc.

All procedures were done over the internet and by mail.


What did we learn from the first TemPredict Study?

  • More than 65,000 participants enrolled in the TemPredict Study. This is more than we thought was possible!

  • We submitted an initial article for publication that includes the first 50 participants who reported COVID-19. It will soon be available in its published form.

  • In this article, we report on early evidence that Oura Ring signals can show signs of change several days before someone becomes sick with COVID-19.

  • If you would like to see the article now, please keep in mind that the article is not yet published and may changed before it is officially published. It is located here:

  • We are hard at work on the data and will share our findings from these analyses with you as soon as we can.

  • About 10,000 TemPredict participants completed mail-based antibody testing. We had to prioritize participants in the U.S. because of shipping costs – we could not afford many of the international shipping rates. We apologize to participants who did not receive kits; we had a limited number and could not provide them to everyone. We want to assure you that your data are still crucial and will be included in analyses.

bottom of page